This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drusano, G. L.
Right arrow Articles by Bye, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drusano, G. L.
Right arrow Articles by Bye, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 913-916, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.913-916.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Rational Dose Selection for a Nonnucleoside Reverse Transcriptase Inhibitor through Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation

G. L. Drusano,1* K. H. P. Moore,2 J. P. Kleim,3 W. Prince,3 and A. Bye3

Division of Clinical Pharmacology, Clinical Research Institute, Albany Medical College, Albany, New York,1 Glaxo-SmithKline, Inc., Research Triangle Park, North Carolina,2 Glaxo-SmithKline R&D, Greenford, United Kingdom3

Received 15 September 2000/ Returned for modification 20 January 2001/ Accepted 22 October 2001

In order to choose a rational dose for GW 420867X, we first set a goal of therapy. We hypothesized that, for optimal antiretroviral activity, the trough free drug concentration should remain above the 90% effective concentration (EC90) of human immunodeficiency virus type 1. We performed population pharmacokinetic analysis on three different doses of GW 420867X (50, 100, and 200 mg). Monte Carlo simulation was performed, assuming a log-normal distribution for 1,000 simulated subjects for each dose, and was repeated three times. The trough concentrations were divided by 76 to account for protein binding and for the difference between EC50 and EC90. We then determined the fraction of the simulated population whose free drug trough concentrations would exceed an EC90 over a broad range of values. The target attainment for all three doses exceeded 95% out to a starting EC50 of 10 nM. For 16 viral isolates, the EC50 range encountered for GW 420867X did not exceed 8 nM, implying that the three doses could not be differentiated by effect in a clinical trial in naive patients. This prediction was shown to be correct in a randomized, double-blind trial with 1 week of monotherapy with GW 420867X.

* Corresponding author. Mailing address: Division of Clinical Pharmacology, Clinical Research Institute, Albany Medical College, Albany, NY 12208. Phone: (518) 262-6330. Fax: (518) 262-6333. E-mail: gldrusano{at}aol.com.

Antimicrobial Agents and Chemotherapy, March 2002, p. 913-916, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.913-916.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • van den Anker, J. N., Pokorna, P., Kinzig-Schippers, M., Martinkova, J., de Groot, R., Drusano, G. L., Sorgel, F. (2009). Meropenem Pharmacokinetics in the Newborn. Antimicrob. Agents Chemother. 53: 3871-3879 [Abstract] [Full Text]  
  • McSharry, J. J., Weng, Q., Brown, A., Kulawy, R., Drusano, G. L. (2009). Prediction of the Pharmacodynamically Linked Variable of Oseltamivir Carboxylate for Influenza A Virus Using an In Vitro Hollow-Fiber Infection Model System. Antimicrob. Agents Chemother. 53: 2375-2381 [Abstract] [Full Text]  
  • Ambrose, P. G., Forrest, A., Craig, W. A., Rubino, C. M., Bhavnani, S. M., Drusano, G. L., Heine, H. S. (2007). Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model. Antimicrob. Agents Chemother. 51: 4351-4355 [Abstract] [Full Text]  
  • Zelenitsky, S., Ariano, R., Harding, G., Forrest, A. (2005). Evaluating Ciprofloxacin Dosing for Pseudomonas aeruginosa Infection by Using Clinical Outcome-Based Monte Carlo Simulations. Antimicrob. Agents Chemother. 49: 4009-4014 [Abstract] [Full Text]  
  • Preston, S. L., Piliero, P. J., Bilello, J. A., Stein, D. S., Symonds, W. T., Drusano, G. L. (2003). In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours. Antimicrob. Agents Chemother. 47: 3393-3399 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»